Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression This randomized clinical trial evaluates the efficacy and safety of bireociclib plus fulvestrant in hormone receptor–positive, ERBB2-negative advanced breast cancer.

Adición de bireociclib a fulvestrant mejora la supervivencia libre de progresión en pacientes con cáncer de mama avanzado HR+ERBB2- con progresión luego de terapia endocrina previa #bireociclib #BreastCancer jamanetwork.com/journals/jam...

🎉 NMPA Approval!
#Bireociclib Tablets (#Xuan Yuening) by #Xuanzhu Biopharmaceutical Co., Ltd. are now approved for HR+/HER2– advanced or metastatic breast cancer.

📧 info@dengyuemed.com
#CDK46Inhibitor #HRPositiveBreastCancer #HER2NegativeBreastCancer #NMPAApproval
#HongKongDengYueMedicine